Cargando…

Hypothyroidism in Context: Where We’ve Been and Where We’re Going

Hypothyroidism affects up to 5% of the general population, with a further estimated 5% being undiagnosed. Over 99% of affected patients suffer from primary hypothyroidism. Worldwide, environmental iodine deficiency is the most common cause of all thyroid disorders, including hypothyroidism, but in a...

Descripción completa

Detalles Bibliográficos
Autores principales: Chiovato, Luca, Magri, Flavia, Carlé, Allan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6822815/
https://www.ncbi.nlm.nih.gov/pubmed/31485975
http://dx.doi.org/10.1007/s12325-019-01080-8
_version_ 1783464412861956096
author Chiovato, Luca
Magri, Flavia
Carlé, Allan
author_facet Chiovato, Luca
Magri, Flavia
Carlé, Allan
author_sort Chiovato, Luca
collection PubMed
description Hypothyroidism affects up to 5% of the general population, with a further estimated 5% being undiagnosed. Over 99% of affected patients suffer from primary hypothyroidism. Worldwide, environmental iodine deficiency is the most common cause of all thyroid disorders, including hypothyroidism, but in areas of iodine sufficiency, Hashimoto’s disease (chronic autoimmune thyroiditis) is the most common cause of thyroid failure. Hypothyroidism is diagnosed biochemically, being overt primary hypothyroidism defined as serum thyroid-stimulating hormone (TSH) concentrations above and thyroxine concentrations below the normal reference range. Symptoms of hypothyroidism are non-specific and include mild to moderate weight gain, fatigue, poor concentration, depression, and menstrual irregularities, while the consequences of untreated or under-treated hypothyroidism include cardiovascular disease and increased mortality. Levothyroxine has long been the main tool for treating hypothyroidism and is one of the world’s most widely prescribed medicines. In adults with overt hypothyroidism, levothyroxine is usually prescribed at a starting dose of 1.6 µg/kg/day, which is then titrated to achieve optimal TSH levels (0.4–4.0 mIU/L), according to the therapeutic target. We here summarise the history of levothyroxine and discuss future issues regarding the optimal treatment of hypothyroidism. Because nearly one-third of patients with treated hypothyroidism still exhibit symptoms, it is important that levothyroxine is used more appropriately to achieve maximum benefit for patients. In order to ensure this, further research should include more accurate assessments of the true prevalence of hypothyroidism in the community, optimisation of the levothyroxine substitution dose, proper duration of treatment, and identification of patients who may benefit from combination therapy with levothyroxine plus levotriiodothyronine. Funding: Merck. Plain Language Summary: Plain language summary available for this article.
format Online
Article
Text
id pubmed-6822815
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Springer Healthcare
record_format MEDLINE/PubMed
spelling pubmed-68228152019-11-06 Hypothyroidism in Context: Where We’ve Been and Where We’re Going Chiovato, Luca Magri, Flavia Carlé, Allan Adv Ther Review Hypothyroidism affects up to 5% of the general population, with a further estimated 5% being undiagnosed. Over 99% of affected patients suffer from primary hypothyroidism. Worldwide, environmental iodine deficiency is the most common cause of all thyroid disorders, including hypothyroidism, but in areas of iodine sufficiency, Hashimoto’s disease (chronic autoimmune thyroiditis) is the most common cause of thyroid failure. Hypothyroidism is diagnosed biochemically, being overt primary hypothyroidism defined as serum thyroid-stimulating hormone (TSH) concentrations above and thyroxine concentrations below the normal reference range. Symptoms of hypothyroidism are non-specific and include mild to moderate weight gain, fatigue, poor concentration, depression, and menstrual irregularities, while the consequences of untreated or under-treated hypothyroidism include cardiovascular disease and increased mortality. Levothyroxine has long been the main tool for treating hypothyroidism and is one of the world’s most widely prescribed medicines. In adults with overt hypothyroidism, levothyroxine is usually prescribed at a starting dose of 1.6 µg/kg/day, which is then titrated to achieve optimal TSH levels (0.4–4.0 mIU/L), according to the therapeutic target. We here summarise the history of levothyroxine and discuss future issues regarding the optimal treatment of hypothyroidism. Because nearly one-third of patients with treated hypothyroidism still exhibit symptoms, it is important that levothyroxine is used more appropriately to achieve maximum benefit for patients. In order to ensure this, further research should include more accurate assessments of the true prevalence of hypothyroidism in the community, optimisation of the levothyroxine substitution dose, proper duration of treatment, and identification of patients who may benefit from combination therapy with levothyroxine plus levotriiodothyronine. Funding: Merck. Plain Language Summary: Plain language summary available for this article. Springer Healthcare 2019-09-04 2019 /pmc/articles/PMC6822815/ /pubmed/31485975 http://dx.doi.org/10.1007/s12325-019-01080-8 Text en © The Author(s) 2019 https://creativecommons.org/licenses/by-nc/4.0/Open AccessThis article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) ), which permits any noncommercial use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
spellingShingle Review
Chiovato, Luca
Magri, Flavia
Carlé, Allan
Hypothyroidism in Context: Where We’ve Been and Where We’re Going
title Hypothyroidism in Context: Where We’ve Been and Where We’re Going
title_full Hypothyroidism in Context: Where We’ve Been and Where We’re Going
title_fullStr Hypothyroidism in Context: Where We’ve Been and Where We’re Going
title_full_unstemmed Hypothyroidism in Context: Where We’ve Been and Where We’re Going
title_short Hypothyroidism in Context: Where We’ve Been and Where We’re Going
title_sort hypothyroidism in context: where we’ve been and where we’re going
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6822815/
https://www.ncbi.nlm.nih.gov/pubmed/31485975
http://dx.doi.org/10.1007/s12325-019-01080-8
work_keys_str_mv AT chiovatoluca hypothyroidismincontextwherewevebeenandwhereweregoing
AT magriflavia hypothyroidismincontextwherewevebeenandwhereweregoing
AT carleallan hypothyroidismincontextwherewevebeenandwhereweregoing